FDA meeting clears the path for RAD101’s pivotal trial in brain metastases imaging
Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX) has completed an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for RAD101, its investigational PET imaging agent for detecting brain metastases. The meeting marks a formal regulatory checkpoint that clears the way for the company to advance toward a pivotal Phase 3 trial in the U.S.
The milestone follows RAD101’s Phase 2b result, in which the agent demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial’s primary endpoint. Radiopharm expects to receive the FDA’s official meeting minutes within approximately 30 days, which will constitute the next near-term catalyst investors should monitor.
When big ASX news breaks, our subscribers know first
What is an End-of-Phase 2 FDA meeting — and why does it matter?
An EOP2 meeting is a formal interaction between a drug or device developer and the FDA, designed to align both parties on the design of pivotal (Phase 3) trials before significant capital is deployed. Think of it as a blueprint sign-off before construction begins: the company presents its proposed trial design, and the FDA provides feedback intended to reduce the risk of a costly misstep later in development.
A constructive EOP2 outcome signals that the FDA has broadly agreed on the regulatory framework, reducing trial design uncertainty and de-risking the path toward a potential New Drug Application (NDA) submission. For RAD101, the FDA’s formal minutes will formalise the pivotal development plan for a product targeting a market of more than 300,000 U.S. patients diagnosed annually with cerebral metastases.
The RAD101 Phase 2b results, published in July 2026, confirmed 93% concordance across all 30 evaluable patients and included preliminary secondary endpoint data showing 86% sensitivity, providing the clinical package that underpinned the FDA EOP2 meeting request.
RAD101 also holds FDA Fast Track Designation, granted specifically to distinguish between recurrent disease and treatment effect in brain metastases originating from solid tumours of different origin, including leptomeningeal disease. Fast Track status can support more frequent FDA engagement and may allow for a rolling NDA review, potentially compressing the timeline to a regulatory decision.
RAD101’s differentiated science and a large unmet market
RAD101 is a novel Fluorine-18-labeled small-molecule imaging agent that selectively targets fatty acid synthase (FASN), a multi-enzyme protein overexpressed in cerebral metastases from solid tumours. By targeting FASN activity, the agent is designed to enable more accurate detection of cancer cells in the central nervous system via PET imaging.
Contrast-enhanced MRI (CE-MRI) is currently the preferred method for imaging intracranial metastatic disease, but it carries limitations, particularly in follow-up surveillance scans. RAD101 is being developed to address that clinical gap.
Positive Phase 2a data from Imperial College London showed significant tumour uptake that was independent of the tumour of origin. That study also indicated that PET-MRI may potentially represent a non-invasive means of predicting overall survival, a finding the researchers noted warranted larger studies.
RAD101’s key clinical credentials to date include:
- FASN-targeting PET imaging agent (18F-labelled small molecule)
- 93% concordance with MRI in Phase 2b, meeting the primary endpoint
- FDA Fast Track Designation
- Imperial College London Phase 2a data: significant tumour uptake independent of tumour origin; potential overall survival prediction signal
- Siemens Healthineers partnership for Phase 3 dose manufacturing and distribution in the U.S.
Phase 3 readiness underway — and strategic partners in focus
Radiopharm is not waiting for the formal FDA minutes before acting. The company has already moved to advance Phase 3 readiness activities, covering both clinical and operational planning, to position the programme for efficient progression once the Agency’s feedback is received. The Siemens Healthineers manufacturing and distribution partnership signals that operational infrastructure is being put in place ahead of the pivotal trial.
The Siemens Healthineers supply agreement, signed in April 2026, covers manufacture and distribution of Fluorine-18-labelled RAD101 across Siemens’ U.S. radiopharmacy network, giving Radiopharm a logistics infrastructure that most Phase 3-stage imaging programmes must still build from scratch.
Chief Executive Officer Riccardo Canevari also indicated that the company is actively evaluating strategic partnering opportunities. Given the regulatory progress and the scale of the addressable market, management has framed this as a value-creation pathway.
Riccardo Canevari, Chief Executive Officer
“The successful completion of our End-of-Phase 2 meeting with the FDA marks a pivotal milestone for RAD101 and an important inflection point in the evolution of our company… We are encouraged by the collaborative dialogue with the Agency and believe this interaction positions us well as we finalize our pivotal development strategy and take the next critical steps toward a potential registration program.”
In a separate comment, Mr. Canevari noted that the company is “evaluating opportunities to engage with potential strategic partners who recognize the value of this program and share our vision for bringing this innovation to patients and clinicians worldwide,” adding that the maturity of the asset makes now an appropriate time to explore such pathways.
The combination of a clear regulatory framework, a major manufacturing partner, Fast Track status, and active partnering discussions positions RAD101 as a maturing asset with a defined path toward a potential U.S. registrational programme.
Key near-term catalysts for RAD101:
| Catalyst | Timeline | Significance | Status |
|---|---|---|---|
| FDA formal meeting minutes | ~30 days | Formalises Phase 3 design framework | Pending |
| Phase 3 readiness activities | Underway now | Clinical and operational planning | Active |
| Strategic partnering evaluation | Ongoing | Potential value-creation pathway | Exploring |
| Phase 3 trial initiation | Post-minutes | Pivotal registrational trial in the U.S. | Planning |
Don’t Miss the Next ASX Healthcare Breakthrough
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis. Over 20,000+ subscribers already rely on Big News Blast to stay ahead of market-moving developments. Click the “Free Alerts” button to start receiving alerts the moment ASX healthcare announcements hit.